Progress of Biologics in Therapeutics of Rheumatoid Arthritis

Chunde Bao

2007-01-01

Abstract:Biologic agents are an important therapeutic option for treating patients with rheumatoid arthritis(RA) since late 90's of last century.Biologic agents have revolutionized the treatment of RA by reducing its signs and symptoms.Current researches of biologics target mainly at cytokines,T and B immunocytes.

What problem does this paper attempt to address?

Biologic Therapy for Crohn's Disease over the Last 3 Decades.

Ji-Liang Shen,Zheng Zhou,Jia-Sheng Cao,Bin Zhang,Jia-Hao Hu,Jia-Ying Li,Xiao-Ming Liu,Sarun Juengpanich,Ming-Song Li,Xu Feng

DOI: https://doi.org/10.12998/wjcc.v10.i2.594

2022-01-01

World Journal of Clinical Cases

Abstract:BACKGROUND:Despite the overload of publications on Crohn's disease (CD), no comprehensive analysis of biologic therapy for CD has been reported.AIM:To determine knowledge gaps and identify areas of interest of biologic therapy for CD.METHODS:The top 100 highest-cited original articles were identified from January 1991 to December 2020 in the Clarivate Analytics Web of Science Core Collection database. We conducted a bibliometric analysis of biologic therapy for CD based on total citations, summarized the bibliographic information of the articles related to CD biologic therapy, and explored the research hotspots.RESULTS:The top 100 highest-cited original articles were identified with total citations ranging from 307 to 2978. The 2000s (Period II, n = 66) yielded the most influential original articles and saw the most dramatic growth. Among the top 10 countries, including 8 European countries and 2 North American countries, the United States (n = 37) and Belgium (n = 20) contributed the most publications. Among the top 10 institutions, the University Hospital Gasthuisberg in Belgium (n = 23), the University of Chicago in the United States (n = 20), and the Mayo Clinic in the United States (n = 17) published the most papers. Regarding authors, Rutgeerts P in Belgium (n = 32), Sandborn WJ in the United States (n = 23), and Feagan BG in Canada (n = 18) published the highest number of studies. The cooperation relationships between the United States and Europe were most frequent. Gastroenterology (impact factor = 22.682) published the most articles on biologic therapy for CD (n = 32) with 17654 total citations. Anti-tumor necrosis factor biologics and monoclonal antibodies were the most studied topics.CONCLUSION:The bibliometric analysis emphasized the key contributions to the development of the specialized field. These data would provide useful research insights into biologic therapy for CD for clinicians and researchers.
The Role of Biologics in Rheumatoid Arthritis: A Narrative Review

Jay P Patel,Nithin Kumar Konanur Srinivasa,Akshay Gande,Madatala Anusha,Hassaan Dar,Dheeraj B Baji

DOI: https://doi.org/10.7759/cureus.33293

2023-01-03

Cureus

Abstract:Rheumatoid arthritis (RA) is a chronic inflammatory joint disease that can cause cartilage and bone damage as well as a disability. Various cytokines play an essential role in disease formation such as tumor necrosis factor (TNF)-alpha, interleukin (IL)-1, IL-6, IL-17, and macrophages; osteoclast is also activated by the cytokines, which cause bone degradation. Early diagnosis is key to optimal therapeutic success, particularly in patients with well-characterized risk factors for poor outcomes such as high disease activity, presence of autoantibodies, and early joint damage. Treatment algorithms involve measuring disease activity with composite indices, applying a treatment-to-target strategy, and using conventional, biological, and new non-biological disease-modifying antirheumatic drugs. After the treatment target of stringent remission (or at least low disease activity) is maintained, dose reduction should be attempted. Although the prospects for most patients are now favorable, many still do not respond to current therapies. The biologics have changed the disease progression over the past few decades, such as TNF-alpha inhibitors (infliximab, etanercept, adalimumab, golimumab, certolizumab), IL-1 inhibitors (anakinra), IL-6 inhibitors (tocilizumab), CD20 inhibitors (rituximab), and cytotoxic T-lymphocyte associated antigen (CTLA)-4 inhibitors (abatacept). In treatment with biologics, only little is known if "biologic-free" remission is possible in patients with sustained remission following intensive biological therapy. Infliximab and etanercept, in the long run, develop the drug antibody. This article has reviewed the action of the cytokine on joints and biological drug's action in blocking the cytokine degradation effect, benefits of biologics, and adverse effects in the long and short term. They are also effective alone or in combination with other drugs.
Non-TNF biologics and their biosimilars in rheumatoid arthritis

Tsz Ching Mok,Chi Chiu Mok

DOI: https://doi.org/10.1080/14712598.2024.2358165

2024-05-24

Expert Opinion on Biological Therapy

Abstract:Introduction Rheumatoid arthritis (RA) is a chronic inflammatory rheumatic disease that affects both the articular and extra-articular structures, leading to significant joint damage, disability and excess mortality. The treatment algorithm of RA has changed tremendously in the past 1–2 decades because of the emergence of novel biological therapies that target different mechanisms of action in addition to TNFα.

medicine, research & experimental,biotechnology & applied microbiology
Biological Therapy of Traditional Therapy-Resistant Adult-Onset Still’s Disease: an Evidence-Based Review

Sha Zhou,Jianjun Qiao,Juan Bai,Yinhua Wu,Hong Fang

DOI: https://doi.org/10.2147/tcrm.s155488

2018-01-01

Therapeutics and Clinical Risk Management

Abstract:Background Biotherapy is becoming increasingly important in the treatment of adult-onset Still’s disease (AOSD). The aim of our study was to evaluate the efficacy and safety of biological therapy for AOSD resistant to traditional therapy. Patients and methods Database of Library of Congress, the PubMed, and Web of Science Core Collection were used to retrieve relevant articles published in English language until March 2017. Only studies published in English language were included, and the additional references quoted in these articles were also checked. Articles concerning the efficacy and safety of all the biotherapies in refractory AOSD were evaluated. Results There were 112 articles available in total; 422 AOSD patients were given at least one biologic. We found that 293 patients (69.43%) had received TNF-α blocking agents (infiliximab, etanercept, and adalimumab), 194 patients (45.97%) were treated with IL-1 receptor antagonists (anakinra, rilonacept, and canakinumab), 163 patients (38.63%) were given IL-6 inhibitor (tocilizumab), and 24 patients (5.69%) received rituximab and abatacept. The efficacy of biological therapy and overall tolerance of biological therapy for refractory AOSD were good. Thirty two of 271 patients given anti-TNF-α therapies (11.81%), 116 patients receiving IL-1 inhibitors (65.54%), 124 patients receiving tocilizumab (76.07%), and 13 patients given other biological therapies (36.11%) achieved remission. Side effects of biologic therapy were infections such as urinary tract infections and soft tissue abscess. Conclusion Our findings suggest that anakinra and tocilizumab may be good choices for the treatment of refractory AOSD considering the effectiveness and safety.
Novel Biologics in Treatment of Psoriatic Arthritis

Jiong ZHOU,Min ZHENG

DOI: https://doi.org/10.3785/j.issn.1008-9292.2009.04.014

2009-01-01

Abstract:Psoriatic arthritis is an inflammatory joint disease associated with psoriasis. Due to difficulty for early diagnosis and lack of effective therapy, the disease leads to chronic course and frequent relapse. Patients may suffer from ankylosis,disability and even death. The past treatments neither can control the disease effectively, nor be capable of inhibiting the development of structural joint damage. Based on the current psoriasis pathogenesis, novel biologics have been developed,which can aim the specific targets, resulting in more effective and safer management for psoriatic arthritis.
[Research Progress on B Cell Surface Molecules Targeted Therapy in Rheumatoid Arthritis].

Wang Di,Yan Chang,Yu-Jing Wu,Wei

2011-01-01

Abstract:Rheumatoid arthritis (RA) is a chronic and systemic autoimmune disease, it's pathogenic mechanism is unknown and there is a lack of safe and effective therapeutic drug on RA. Because of important function of B cells in RA pathogenic mechanism, many therapeutic drugs targeted on different positions of B cells are emerging in RA therapy. These B cell-targeted therapeutic biologic agents include anti-CD20 monoclonal antibody (such as rituximab, ocrelizumab and ofatumumab), biologic agents which targeted B lymphocyte stimulator (BLyS) and their receptors (such as belimumab and atacicept), anti-CD22 monoclonal antibody and CD40/CD40L co-stimulation reaction blocker. Efficacy of above-mentioned targeting agents has confirmed in studies of RA and it's animal models, suggesting that it is a promising therapeutic strategy that B cells are regarded as targeting position in RA therapy.
Optimal Therapy of Biologics in Crohn′s Disease

Wang Yufang,Gu Yubei,Shen Jun,Gao Xiang,Cao Qian

DOI: https://doi.org/10.3760/cma.j.issn.2096-367x.2019.03.021

2019-01-01

Abstract:Biologics have been widely used for the treatment of Crohn′s disease in clinical practice. Optimal therapy includes appropriate selection of patient and timing when initiating biologics,therapeutic drug monitoring during treatment and personalized withdrawal strategy when exiting. Treatment optimization strategy will help to improve efficacy and safety of biologics.
Therapy Development of B iological Agents in Inflammatory Arthritis

Zhao-xing TIAN,Ying-shan HUANG,Ya-an ZHENG

2009-01-01

Abstract:Inflammatory arthritis is a group of chronic,progressive inflammatory condition that can lead to significant disability and severe joint pains,influencing the life quality of patient severely.The treatment of inflammatory arthritis is very difficult.Multiple previous medical treatments have showed poor effectiveness,long period,difficulty to induce remission,being easy to recur,and severe side effects.Recently,biological agents developed rapidly.They have been widely used in the treatment of inflammatory arthritis.Bio-logical agents have a good curative effect on the cases.They appear rapidly and have abiding effect.The use of biological agents is a sym-bol of the era of targeted therapy.Currently,the majorside effects of biological agents are inducing infection and tumors.Here we have reviewed the recent research progress about biological agents in treating inflammatory arthritis from its classification,peculiarity and clin-ical application.
[Biologic agents for the treatment of rheumatic diseases]

Yoshiya Tanaka

Abstract:Rheumatoid arthritis (RA) is a systemic inflammatory disease characterized by chronic synovitis and bone damage. Bone homeostasis is maintained by a balance between bone resorption and bone formation. It is also involved by immune systems and imbalance in immune system often results in pathological processes such as joint destruction as well as secondary osteoporosis. Proinflammatory cytokines such as TNF and IL-6 cause an imbalance in bone metabolism via direct and/or indirect effects on osteoclasts. However, the combination of methotrexate and biologic DMARDs targeting TNF and IL-6 have revolutionized the treatment of RA, producing significant improvements in clinical, radiographic, and functional outcomes that were not previously observed. Such progress in the treatment of RA has been expanded to other joint diseases including psoriatic arthritis, spodylarthritis and so on.
Research progress in the treatment of rheumatoid arthritis

DOI: https://doi.org/10.33140/jcrc.07.05.01

2022-05-12

Journal of Clinical Review & Case Reports

Abstract:Rheumatoid arthritis RA is a systemic immune inflammation of unknown etiology, which mainly damages the synovium of the joints, leading to joint deformities and loss of function. Its drug treatment currently includes traditional anti-rheumatic drugs, biological agents and various biosimilars. Biological agents have shown obvious advantages in recent years and have been widely used. In recent years, there have been many research related to new treatment methods, such as: microbial therapy, tuned cationic dendrimer therapy, etc. This article focuses on the review of new developments in rheumatoid arthritis treatment drugs and methods.
Recent progress in treatments of rheumatoid arthritis: an overview of developments in biologics and small molecules, and remaining unmet needs

Yoshiya Tanaka

DOI: https://doi.org/10.1093/rheumatology/keab609

2021-11-01

Rheumatology

Abstract:Abstract Through treatment with biological DMARDs (bDMARDs) or targeted synthetic (tsDMARDs) such as Janus kinase (JAK) inhibitors in addition to MTX, clinical remission has become a realistic therapeutic goal for the majority of patients with RA, and sustained remission facilitates prevention of joint damage and physical dysfunction. Long-term safety and sustained inhibition of structural changes and physical dysfunction by bDMARDs have been reported. The development of next-generation bDMARDs and expansion of their indications to various autoimmune diseases are expected. Five JAK inhibitors show comparable efficacy to bDMARDs, and the latest ones are effective for overcoming difficult-to-treat RA regardless of prior medications. Patients treated with JAK inhibitors should be adequately screened and monitored for infection, cardiovascular disorders, thrombosis, malignancies and so on. Advances in therapeutic strategies, including the differential use of therapeutic drugs and de-escalation of treatment after remission induction, are prioritized.

rheumatology
Biologic Drugs for Rheumatoid Arthritis in the Context of Biosimilars, Genetics, Epigenetics and COVID-19 Treatment

Krzysztof Bonek,Leszek Roszkowski,Magdalena Massalska,Wlodzimierz Maslinski,Marzena Ciechomska

DOI: https://doi.org/10.3390/cells10020323

IF: 6

2021-02-04

Cells

Abstract:Rheumatoid arthritis (RA) affects around 1.2% of the adult population. RA is one of the main reasons for work disability and premature retirement, thus substantially increasing social and economic burden. Biological disease-modifying antirheumatic drugs (bDMARDs) were shown to be an effective therapy especially in those rheumatoid arthritis (RA) patients, who did not adequately respond to conventional synthetic DMARD therapy. However, despite the proven efficacy, the high cost of the therapy resulted in limitation of the widespread use and unequal access to the care. The introduction of biosimilars, which are much cheaper relative to original drugs, may facilitate the achievement of the therapy by a much broader spectrum of patients. In this review we present the properties of original biologic agents based on cytokine-targeted (blockers of TNF, IL-6, IL-1, GM-CSF) and cell-targeted therapies (aimed to inhibit T cells and B cells properties) as well as biosimilars used in rheumatology. We also analyze the latest update of bDMARDs’ possible influence on DNA methylation, miRNA expression and histone modification in RA patients, what might be the important factors toward precise and personalized RA treatment. In addition, during the COVID-19 outbreak, we discuss the usage of biologicals in context of effective and safe COVID-19 treatment. Therefore, early diagnosing along with therapeutic intervention based on personalized drugs targeting disease-specific genes is still needed to relieve symptoms and to improve the quality of life of RA patients.

cell biology
The impact of biologic agents on cardiovascular risk factors in patients with rheumatoid arthritis: A meta analysis

Xiaodong Jia,Zheming Yang,Jiayin Li,Zhu Mei,Lihui Jia,Chenghui Yan

DOI: https://doi.org/10.1371/journal.pone.0306513

IF: 3.7

2024-08-29

PLoS ONE

Abstract:Objective: The purpose of the study is to evaluate the effects of biologic therapy on cardiovascular risk factors in rheumatoid arthritis patients to determine its clinical efficacy. Methods: Relevant literature was systematically searched in PubMed, Embase, and Cochrane Library databases. Meta-analysis was conducted using standardized mean differences (SMDs) and 95% confidence intervals (CIs) to evaluate cardiovascular risk factors and atherosclerosis. Heterogeneity, sensitivity analysis, and publication bias were assessed. Statistical significance was set at P<0.05. Results: The meta-analysis revealed that biologic treatment in RA patients was associated with decreased high-density lipoprotein cholesterol (HDL-C) levels compared to controls (MD: -0.10, 95% CI: [-0.14, -0.05], P<0.0001). Subgroup analysis based on treatment duration showed heterogeneity and a potential decrease in total cholesterol levels after 12 months of treatment (MD = -0.03, 95% CI [-0.21, -0.15], P = 0.76). Biologic therapy significantly reduced triglyceride levels compared to controls (MD = -0.23, 95% CI [-0.37, -0.09], P = 0.001), as observed in subgroup analysis. Moreover, biologics effectively decreased low-density lipoprotein cholesterol (LDL-C) levels (MD: -0.10, 95% CI: [-0.14, -0.05], P<0.0001). However, biologic treatment was associated with increased inner carotid artery thickness (MD: 0.05, 95% CI: [0.03, 0.07], P<0.0001), indicating potential adverse effects on cardiovascular health. No significant effect on pulse wave velocity (PWV) was observed (MD: -0.23, 95% CI: [-0.80, 0.34], P = 0.43, I2 = 0%, P = 0.55). Conclusion: Biologic agents may improve lipid profiles in RA patients but could also have adverse effects on cardiovascular health. Further research is needed to comprehensively understand the impact of biologic therapy on lipid metabolism and cardiovascular outcomes in RA patients. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/, CRD42024504911.
Treatment of Reactive Arthritis with Biological Agents

Avarna Agarwal,Debashis Maikap,Prasanta Padhan

DOI: https://doi.org/10.1007/s11926-024-01165-6

Abstract:Purpose of the review: Reactive arthritis (ReA) is an inflammatory joint condition triggered by an infection elsewhere in the body, and this review aims to provide a comprehensive synthesis of recent studies including case reports and case series to determine whether biologics are a treatment option. Recent findings: Recent studies indicate that biological agents, including anti-TNF agents (infliximab, adalimumab, etanercept), anti-IL17 (secukinumab), and anti-IL6 (tocilizumab), are effective in treating refractory cases of ReA. Evidence suggests these agents are associated with significant clinical improvement. Notably, the data reveal that these biologics are generally well-tolerated, with a low incidence of major adverse events, which supports their safety profile for use in ReA. Biological agents, including anti-TNF, anti-IL17, and anti-IL6 therapies, can be safely and effectively used in the treatment of ReA when conventional therapies fail. It further emphasizes the need for a well-designed controlled trial to provide scientific basis for better informed clinical decisions in cases not responding to conventional treatment.
Unveiling Novel Drug Targets and Emerging Therapies for Rheumatoid Arthritis: A Comprehensive Review

Manoj Khokhar,Sangita Dey,Sojit Tomo,Mariusz Jaremko,Abdul-Hamid Emwas,Rajan Kumar Pandey

DOI: https://doi.org/10.1021/acsptsci.4c00067

2024-05-28

Abstract:Rheumatoid arthritis (RA) is a chronic debilitating autoimmune disease, that causes joint damage, deformities, and decreased functionality. In addition, RA can also impact organs like the skin, lungs, eyes, and blood vessels. This autoimmune condition arises when the immune system erroneously targets the joint synovial membrane, resulting in synovitis, pannus formation, and cartilage damage. RA treatment is often holistic, integrating medication, physical therapy, and lifestyle modifications. Its main objective is to achieve remission or low disease activity by utilizing a "treat-to-target" approach that optimizes drug usage and dose adjustments based on clinical response and disease activity markers. The primary RA treatment uses disease-modifying antirheumatic drugs (DMARDs) that help to interrupt the inflammatory process. When there is an inadequate response, a combination of biologicals and DMARDs is recommended. Biological therapies target inflammatory pathways and have shown promising results in managing RA symptoms. Close monitoring for adverse effects and disease progression is critical to ensure optimal treatment outcomes. A deeper understanding of the pathways and mechanisms will allow new treatment strategies that minimize adverse effects and maintain quality of life. This review discusses the potential targets that can be used for designing and implementing precision medicine in RA treatment, spotlighting the latest breakthroughs in biologics, JAK inhibitors, IL-6 receptor antagonists, TNF blockers, and disease-modifying noncoding RNAs.
Current and Emerging DMARDs for the Treatment of Rheumatoid Arthritis

Analí Lizárraga,M. Caubet,E. Mysler

DOI: https://doi.org/10.2147/OARRR.S282627

2021-06-01

Open Access Rheumatology: Research and Reviews

Abstract:Abstract Rheumatoid arthritis (RA) is the most prevalent form of inflammatory arthritis. It is a profoundly serious and severe disease that if it goes untreated could have severe consequences to the joints and health of the patient who carries this diagnosis. The treatment of RA has dramatically changed since the year 2000, with the discovery of the TNFis, then other biologics, and finally the JAKi. All these new medications with or without methotrexate in combination, tight control and treat to target have produced a revolution in the outcome of this disease. We reviewed and summarized the treatment options, and the most significant papers for each one of these new drugs. The reader could have a full picture with all the references of the recent publications. We also updated the biosimilar situation in RA, as well as the new drugs that will be coming to the market in the next 5 years.

Medicine
Rheumatoid arthritis: advances in treatment strategies

Peeyush Prasad,Sneha Verma,Surbhi,Nirmal Kumar Ganguly,Ved Chaturvedi,Shivani Arora Mittal

DOI: https://doi.org/10.1007/s11010-022-04492-3

IF: 3.842

2022-06-22

Molecular and Cellular Biochemistry

Abstract:Rheumatoid arthritis (RA) is characterised by severe joint and bone damage due to heightened autoimmune response at the articular sites. Worldwide annual incidence and prevalence rate of RA is 3 cases per 10,000 population and 1%, respectively. Several genetic and environmental (microbiota, smoking, infectious agents) factors contribute to its pathogenesis. Although convention treatment strategies, predominantly Disease Modifying Anti Rheumatic Drugs (DMARDs) and Glucocorticoids (GC), are unchanged as the primary line of treatment; novel strategies consisting of biological DMARDs, are being developed and explored. Personalized approaches using biologicals targetspecific pathways associated with disease progression. However, considering the economic burden and side-effects associated with these, there is an unmet need on strategies for early stratification of the inadequate responders with cDMARDs. As RA is a complex disease with a variable remission rate, it is important not only to evaluate the current status of drugs in clinical practice but also those with the potential of personalised therapeutics. Here, we provide comprehensive data on the treatment strategies in RA, including studies exploring various combination strategies in clinical trials. Our systematic analysis of current literature found that conventional DMARDs along with glucocorticoid may be best suited for early RA cases and a combination of conventional and targeted DMARDs could be effective for treating seronegative patients with moderate to high RA activity. Clinical trials with insufficient responders to Methotrexate suggest that adding biologicals may help in such cases. However, certain adverse events associated with the current therapy advocate exploring novel therapeutic approaches such as gene therapy, mesenchymal stem cell therapy in future.

cell biology
Advances in antibody engineering for rheumatic diseases

Anja S. Schmid,Dario Neri

DOI: https://doi.org/10.1038/s41584-019-0188-8

IF: 32.286

2019-02-27

Nature Reviews Rheumatology

Abstract:The advent of biologic therapies, particularly antibody therapeutics, has revolutionized the pharmacological treatment of many rheumatic diseases. Antibody discovery began with the immunization of mice for the production of rodent immunoglobulins, but advances in protein and genetic engineering have now made it possible to generate fully human antibodies, which are better tolerated by patients. For most clinical applications in rheumatology, antibodies have been used as blocking agents capable of neutralizing the function of pro-inflammatory proteins, such as TNF. The latest strategies involve antibody products armed with effector moieties, such as anti-inflammatory drugs or cytokines, or antibody products that are specific for multiple targets for the selective inhibition of inflammation at sites of disease. Antibodies are some of the best-selling drugs in the world, and with further advances in antibody development, engineering of armed antibodies and bispecific products will have an important role in the treatment of rheumatic diseases.

rheumatology
Approaches to optimising access to NICE-approved biologic anti-TNFs for patients with rheumatoid arthritis with moderately active disease

Peter C Taylor,Ayman Askari,Ernest Choy,Michael R Ehrenstein,Sara Else,Muhammad K Nisar

DOI: https://doi.org/10.1186/s12916-023-02746-5

2023-02-14

Abstract:Background: Rheumatoid arthritis (RA) is a chronic inflammatory disease that is associated with joint pain and stiffness. Biologics represent some of the most effective treatments for RA, but previous guidance from the National Institute for Health and Care Excellence (NICE) has limited their use to patients with severely active disease. This has meant patients with moderately active RA have been treated as if they have an acceptable disease state, despite many cases where the inflammation has a major impact on joint damage, mobility, pain and quality of life. However, recent guideline changes (NICE TA715) have approved the use of three biologics - adalimumab, etanercept and infliximab - for the treatment of moderately active RA. Main body: In response to these changes, we have held discussions with medical teams from across the UK to consider the main implications for implementation of these new recommendations, as well as any differences in approach that may exist at a local level. Several key challenges were identified. These included establishing methods of educating both physicians and patients concerning the new availability of the biologic treatments, with suggestions of various organisations that could be approached to circulate informative material. Identifying which patients with moderately active RA stand to benefit was another discussion topic. Relying solely on scoring systems like Disease Activity Score in 28 Joints (DAS28) was acknowledged to have limitations, and alternative complementary approaches such as ultrasound, as well as assessing a patient's co-morbidities, could also be useful tools in determining those who could benefit from biologics. An additional challenge for the process of patient identification has been the increase in the use of telemedicine consultations in response to the coronavirus disease 2019 (COVID-19) pandemic. More use of patient-reported outcomes was raised as one possible solution, and the importance of maintaining up-to-date databases on patient disease scores and treatment history was also stressed. Conclusion: While challenges exist in education and identifying patients who may benefit from the use of biologics, the NICE TA715 recommendations hold great potential in addressing an unmet need for the treatment of moderate RA.
Therapeutic advances in rheumatoid arthritis

Philip Brown,Arthur G Pratt,Kimme L Hyrich

DOI: https://doi.org/10.1136/bmj-2022-070856

2024-01-18

BMJ

Abstract:Rheumatoid arthritis (RA) is one of the most common immune mediated inflammatory diseases. People with rheumatoid arthritis present with pain, swelling, and stiffness that typically affects symmetrically distributed small and large joints. Without effective treatment, significant joint damage, disability, and work loss develop, owing to chronic inflammation of the joint lining (synovium). Over the past 25 years, the management of this condition has been revolutionized, resulting in substantially higher levels of disease remission and better long term outcomes. This improvement reflects a paradigm shift towards early and aggressive pharmacological intervention coupled with a proliferation in treatment choice, in turn related to enhanced pathobiological understanding and the advent of new drugs for rheumatoid arthritis. Following an overview of these developments from a historical perspective, and with a general audience in mind, this review focuses on newer, targeted treatments in an ever evolving landscape. The review highlights ongoing areas of debate and unmet need, including the proportion of patients with persistent, difficult-to-treat disease, despite recent advances. Also discussed are personalized, strategic approaches to individual patients, the role for imaging in clinical decision making, and the goal of sustained, drug free remission and disease prevention in the future.

medicine, general & internal

Progress of Biologics in Therapeutics of Rheumatoid Arthritis

Biologic Therapy for Crohn's Disease over the Last 3 Decades.

The Role of Biologics in Rheumatoid Arthritis: A Narrative Review

Non-TNF biologics and their biosimilars in rheumatoid arthritis

Biological Therapy of Traditional Therapy-Resistant Adult-Onset Still’s Disease: an Evidence-Based Review

Novel Biologics in Treatment of Psoriatic Arthritis

[Research Progress on B Cell Surface Molecules Targeted Therapy in Rheumatoid Arthritis].

Optimal Therapy of Biologics in Crohn′s Disease

Therapy Development of B iological Agents in Inflammatory Arthritis

[Biologic agents for the treatment of rheumatic diseases]

Research progress in the treatment of rheumatoid arthritis

Recent progress in treatments of rheumatoid arthritis: an overview of developments in biologics and small molecules, and remaining unmet needs

Biologic Drugs for Rheumatoid Arthritis in the Context of Biosimilars, Genetics, Epigenetics and COVID-19 Treatment

The impact of biologic agents on cardiovascular risk factors in patients with rheumatoid arthritis: A meta analysis

Treatment of Reactive Arthritis with Biological Agents

Unveiling Novel Drug Targets and Emerging Therapies for Rheumatoid Arthritis: A Comprehensive Review

Current and Emerging DMARDs for the Treatment of Rheumatoid Arthritis

Rheumatoid arthritis: advances in treatment strategies

Advances in antibody engineering for rheumatic diseases

Approaches to optimising access to NICE-approved biologic anti-TNFs for patients with rheumatoid arthritis with moderately active disease

Therapeutic advances in rheumatoid arthritis